This is a double-blind, placebo-controlled, parallel group study designed to assess the
tolerability and efficacy of fsCBD and bsCBD, compared to a placebo control, to reduce opioid
use, anxiety, and pain and improve sleep and cognitive function. If eligible for the study,
subjects will be randomized to receive one of the conditions for 12 weeks.